Report library

Abraxane

Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.

February 26, 2020

Ischemic Stroke Market and Forecast Analysis 2024

Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death.

January 7, 2019

Market Spotlight: Neuropathic Pain

This Market Spotlight report covers the neuropathic pain market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

July 28, 2022

Ertugliflozin

Ertugliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor in Phase III clinical trials for the treatment of type 2 diabetes.

Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Market Spotlight: Atrial Fibrillation

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

August 25, 2022

Betaseron

Betaseron was the first drug to reach the market that modifies the course of multiple sclerosis (MS), after launching in the US in 1994 and the EU in 1996 (where it is marketed as Betaferon).

November 24, 2017

Flolan

In 1995, GlaxoSmithKline’s Flolan (epoprostenol) became the first therapy to be specifically approved for the orphan disease of pulmonary arterial hypertension (PAH).

June 25, 2014

Multiple Sclerosis (MS) KOL Interview – US, Midwest

In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Adynovate

Adynovate is a long-acting PEGylated recombinant factor VIII (rfVIII) therapy developed by Baxalta and Nektar Therapeutics as a follow-on to Advate (rfVIII; Shire).

May 4, 2018

Market Spotlight: Glioblastoma

This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue.

October 8, 2020

Tresiba

Tresiba (insulin degludec; Novo Nordisk) is an ultra-long-acting basal insulin analog approved for the treatment of type 1 and type 2 diabetes in Japan and Europe since October 2012 and January 2013, respectively.

Intersection Between Tech and Pharma KOL Interview

Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

January 12, 2016

Non-Small Cell Lung Cancer KOL Interview – NH, US

$1,099.00

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Dengvaxia

Dengvaxia (tetravalent live-attenuated chimeric vaccine; Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric live-attenuated vaccines (LAVs).

January 4, 2018

Market Spotlight: Hypogonadism

The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.

June 3, 2022

Data in Healthcare: Underpinning the Shift to Value

$2,995.00

Data plays a key role in healthcare systems’ shifts towards value-focused outcomes. Such data includes outcomes and cost data, adherence data, and increasingly, patient-reported data, behavioral and social media data.

November 23, 2016

Ovarian Cancer KOL Interview – UK

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, ofranergene obadenovec, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

April 2, 2020

Gleevec

Gleevec (imatinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor (TKI). The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation.

December 7, 2017

Asia-Pacific: Surgical Procedure Volumes

$5,250.00

This report examines the healthcare trends in Asia-Pacific countries (Japan, China, South Korea, India, Thailand, Vietnam, Malaysia and Australia), as well as analyzes and forecasts (toward 2019).

September 1, 2015

Torisel

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

March 6, 2019

Glyxambi

Glyxambi is a fixed-dose combination of sodium-glucose cotransporter-2 inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) and dipeptidyl peptidase-IV inhibitor Tradjenta.

Global Neurostimulation Devices Market, June 2016

The large and burgeoning global market for implantable neurostimulation devices is approaching nearly $4 billion worldwide. Despite lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of innovative startups and leading medical device companies.

June 1, 2016

Nuplazid

Nuplazid (Acadia Pharmaceuticals) contains pimavanserin, which is a selective serotonin inverse agonist preferentially targeting the serotonin 5-HT2A receptors.

March 19, 2018

Datamonitor Schizophrenia KOL Interview 2

KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

February 24, 2016

Treatment of VTE – US KOL Interview

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 2, 2015

Biomedtracker Diabetic Nephropathy/Diabetic Kidney Disease KOL Interview

Biomedtracker interviewed a nephrologist based in the US Midwest to determine his views on the drugs in development for diabetic nephropathy/diabetic kidney disease.

May 13, 2016

U.S. Benign Uterine Conditions Therapy Systems Market

$3,750.00

This report presents an overview of the most common types of treatment for the benign uterine conditions of menorrhagia and uterine fibroids/polyps; among these therapies are dilation and curettage, hysterectomy, hysteroscopy, and myomectomy. Market and competitive analyses for the medical devices used in these treatments also are presented.

May 1, 2013

Ivosidenib

Ivosidenib is an oral selective reversible inhibitor of the mutant form of the IDH1 enzyme that is associated with a wide range of cancers, including approximately 6–9% of AML cases.

July 6, 2017

Specialty Endoscopic Surgery Devices Market

The global market for specialty endoscopic surgery products totaled approximately $5.8bn in 2016, with the US comprising 48.2% of sales (or $2.8bn). Six major product segments are included in the specialty endoscopic surgery products market: endoscopes and equipment; suction/irrigation and fluid management systems, arthroscopic hand instruments, ENT/neurologic hand instruments, thoracoscopic hand instruments, and trocars.

August 23, 2017

Yervoy

Yervoy (ipilimumab; Bristol-Myers Squibb/Ono Pharmaceutical) is an intravenous fully humanized immunoglobulin-G1 monoclonal antibody that targets human cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).

May 23, 2018

Yonsa

Yonsa (Churchill Pharmaceuticals) is an oral, ultramicrosize tablet formulation of abiraterone acetate that inhibits 17 alpha-hydroxylase (CYP17). The CYP17 family of enzymes catalyze the hydroxylation of intermediates involved in testosterone synthesis, a common driver of prostate cancer genesis and recurrence.

January 18, 2018

Transcatheter Heart Valve Repair and Replacement Devices

In 2020, the global market for transcatheter heart valve management products, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve (TMV) repair products, totaled nearly $4.7bn, with TAVR products accounting for nearly 90% of sales.

August 30, 2021

Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

August 18, 2017

Multiple Sclerosis (MS) KOL Interview – UK, London

In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Specialty Endoscopic Surgery Devices – July 2019

This Meddevicetracker report provides an analysis of the market for specialty endoscopic surgery devices (including access devices, endoscopes and equipment, hand instruments, and suction/irrigation and fluid management systems). Geographic segments covered include the US, five major EU markets, Japan, and the rest of the world.

July 3, 2019

Market Spotlight: Glaucoma

This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

July 18, 2022

Lusefi

Lusefi (luseogliflozin; Taisho) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.

ECLIPSE Psoriasis Pulse Survey

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

January 31, 2019

APL-130277

APL-130277 (Dainippon Sumitomo/Sunovion) is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist.

June 21, 2018

Market Spotlight: Hidradenitis Suppurativa

All of the approved drugs for hidradenitis suppurativa (HS) target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, while Humira and Yuflyma are also available in intravenous formulations.

June 3, 2022

Invokana

Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.

February 27, 2019

Dupixent

Dupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13.

February 16, 2018

Market Spotlight: Axial Spondyloarthritis (axSpA)

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

June 16, 2022